- Details
- Jeremie Calais joins Phillip Koo on UroToday where they discuss the first annual PSMA conference hosted by UCLA and UCSF in partnership with Prostate Cancer Foundation. (PCF). The conference topics include PSMA theranostics in prostate cancer and aim to leverage early experiences and global collaborations in PSMA clinical use. It featured a multidisciplinary panel of experts from around the world,...
|
- Details
- Andrea Miyahira talks with Louise Emmett who shares her unconventional journey into nuclear medicine, sparked by a contrarian spirit and a suggestion against pursuing the field. Initially specializing in nuclear cardiology in Canada, she shifted to theranostics and nuclear medicine, driven by the dynamic growth in these areas. Dr. Emmett discusses the challenges and excitement of running clinical...
|
- Details
- Alicia Morgans speaks with Louise Emmett about the ENZA-p study, presented at ESMO 2023. This groundbreaking research explores the combination of lutetium and enzalutamide in treating early metastatic castrate-resistant prostate cancer. Patients, previously showing limited response to enzalutamide, were screened with PSMA PET and randomized to receive either enzalutamide alone or combined with lut...
|
- Details
- Zach Klaassen hosts Michael Hofman and Renu Eapen to discuss the LuTectomy trial, published in European Urology. The trial explores the use of Lutetium-PSMA-617 as a neoadjuvant treatment in prostate cancer surgery. Initially, the trial included both radiation and surgical arms, but later focused solely on the surgical approach. The study enrolled high-risk prostate cancer patients, with 20 partic...
|
- Details
- Alan Bryce discusses the PSMAfore and other trials with Zach Klaassen. The trial, focusing on lutetium treatment for metastatic castration-resistant prostate cancer (mCRPC) in a pre-chemotherapy setting, shows a significant radiographic progression-free survival (rPFS) benefit. Dr. Bryce highlights the importance of selecting appropriate patients through PSMA PET scans prior to initiating treatmen...
|
- Details
- Zach Klaassen speaks with Andrea Miyahira about the Prostate Cancer Foundation’s (PCF) significant contributions to the development of PSMA theranostics in prostate cancer. Celebrating its 30th anniversary, PCF has invested over $30 million in PSMA-related research, leading to FDA-approved imaging agents and therapies like Pluvicto. Dr. Miyahira outlines the foundation's future focus, including fu...
|
- Details
- In a comprehensive discussion with Phillip Koo, Bill Oresick outlines the process of integrating a Lutetium-177-PSMA program into a large urology group practice. Mr. Oresick emphasizes the importance of thorough research and cost analysis before launching any Radioligand Therapy (RLT) program. He highlights the need for a qualified physicist and a nuclear medicine technologist to ensure safety and...
|
- Details
- Specialized laboratories, which are called hot laboratories, are specially designed and equipped to handle radioactive materials of high activity, including plutonium and transplutonium elements. The handling of lutetium presents special radiation protection and safety because of its high specific activity and radiotoxicity. Therefore, the planning, design, construction, and operation of hot labor...
|
- Details
- In a detailed conversation with Phillip Koo, Gordon Brown delves into the clinical considerations of integrating PLUVICTO into urology practices. Dr. Brown explains the role of Summit Health's navigation team in identifying and monitoring patients for advanced prostate cancer therapies. He discusses the criteria for patient selection, emphasizing the importance of PSMA PET imaging, which is outsou...
|
- Details
- In this discussion, Phillip Koo converses with Chrissy Fareri focusing on the patient journey in a Lutetium-177 PSMA program. Dr. Fareri outlines the nurse navigator's role in guiding patients through a nine-month treatment period, including lab reviews and side effect management. She emphasizes the importance of hydration and provides insights into the personalized service offered at Summit Healt...
|
